Navigation Links
American Scientific Resources To Be Exclusive Seller of World's Only FDA Approved Home Needle Destruction Device
Date:8/19/2009

WESTON, Fla., Aug. 19 /PRNewswire-FirstCall/ -- In keeping with its mission to provide unique products that greatly benefit the wellbeing of families, American Scientific Resources (the Company) (Pink Sheets: ASFX), today announced it has obtained from Safeguard Medical Technologies, LLC exclusive worldwide rights to sell and market home Needle Destruction Devices (NDD) known as the Disintegrator(TM) and the Disintegrator Plus(TM).

All current and future sales and contracts worldwide have been granted to the Company.

Currently the only NDD approved for home use by the U.S. Food and Drug Administration, the Disintegrator enables patients who need to give themselves injections to properly and safely dispose of their used needles at home. The Disintegrator utilizes a unique plasma arc to melt the needle at a temperature of over 3000 degrees Fahrenheit (ensuring the elimination of any pathogens), reducing it to a small bb-shaped ball. It uses patented technology that gives it distinct advantages over similar devices.

"We are quite pleased to have acquired exclusivity on such an innovative product as the Disintegrator," stated Dr. Christopher F. Tirotta, CEO of American Scientific Resources, Inc. "Potential worldwide sales look most encouraging."

The Disintegrator has enormous potential to become a world leader in its market. For example, multiple sclerosis, diabetes and HIV Patients may require daily injections; this device will ensure that their syringes do not end up harming anyone from family members to waste haulers.

A congressional bill (S, 1312) is pending which would amend Title XVIII of the Social Security Act to provide for coverage of supplies associated with the injection of insulin, of containment, removal, decontamination, and disposal of home-generated needles, and syringes, through a sharps container, or decontamination/destruction device under part D of the Medicare program.

The Disintegrator is already gaining a warm reception from the market. In March 2009, Safeguard delivered 5000 units to one of the world's largest healthcare enterprises. Since then, that global enterprise has placed an additional order for 2000 Disintegrator units (which American Scientific Resources will fulfill) and a competing healthcare enterprise has expressed interest to procure an even larger supply than the combined orders above.

Additionally, according to Safeguard, the first enterprise has a specialty injection drug that is one of the top selling drugs in their line up. Eventually they would like to have a Disintegrator in every such user's home in the EU within 3 years; that translates to over 200,000 units; there are approximately 2 million specialty injection drug users worldwide. With health care transitioning into the home from the facility, ASFX sees the device as a global leader in Needle Disposal Technology.

The Company plans to introduce the product commercially in the fall of 2009. The private label, proprietary models being marketed to the large healthcare enterprises will be sold for upwards of $120. The Disintegrator is EPA recommended.

About American Scientific Resources, Inc.

American Scientific Resources, Inc. is a holding company for two wholly owned subsidiaries, Kidz-Med, Inc. and Heart Smart System. The Company's objective is to locate and acquire innovative health and safety products that are successfully sold abroad, and to introduce and promote them to the North American market. For information, visit the corporate web site at www.americansci.com and the Company's subsidiary, Kidz-Med, Inc. at www.kidzmed.com.

Safe Harbor

This release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approvals for anticipated actions.

    Contact
    AudioStocks.com
    Ronald Garner
    Investor Hotline:
    619-293-0621
    ron@bcgu.com


'/>"/>
SOURCE American Scientific Resources, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. SportCoatings; The North American Booster Club Association (NABCA); the Coatings Specialist Group New Booster Program Goes High Tech With Invisible Antimicrobial Defense
3. American Stock Exchange Lists The Common Stock Of Neuralstem, Inc.
4. American Oriental Bioengineering Announces Participation in September Investor Conferences
5. Nektar Presents Positive Results from Phase 1 Clinical Trial of NKTR-118 (oral PEG-naloxol) at American College of Clinical Pharmacology Meeting
6. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
7. Tips from the Journals of the American Society for Microbiology
8. Trubion Pharmaceuticals Announces Upcoming Presentations at American College of Rheumatology Annual Scientific Meeting
9. Americas Heartland Launches Third Season Highlighting Contributions of American Farmers and Ranchers
10. American and European Parkinsons Sufferers Find Chinese Stem Cell Treatment Effective, Proving Western Debates Moot
11. AUDIO from Medialink and Pfizer: Hispanic Heritage Month Reminds Us Increasing Numbers of Hispanic-Americans Do Not Have Health Insurance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... More than $4.3 million was raised last night ... ). The gala was held at the American Museum of ... and honored Alan Alda and P. ... medicine and the public understanding of science. Since the first ... has raised $40 million for the Laboratory,s research and education ...
(Date:12/2/2016)... ... December 01, 2016 , ... ACEA Biosciences, Inc. announced today ... clinical trials for AC0010 at the World Conference on Lung Cancer 2016, taking place ... on the phase I/II clinical trials for AC0010 in patients with advanced non-small cell ...
(Date:12/2/2016)... (PRWEB) , ... December 01, 2016 , ... DrugDev ... industry-wide collaboration, standardization and a beautiful technology experience. All three tenets were on display ... 100 clinical trial leaders from over 40 sponsor, CRO and site organizations to discuss ...
(Date:12/2/2016)... The immunohistochemistry (IHC) market is projected to reach USD ... the forecast period of 2016 to 2021 dominated by immunohistochemistry (IHC) ... largest share of immunohistochemistry (IHC) market, by end user.   ... , , ... 225 pages, profiling 10 companies and supported with 181 tables and ...
Breaking Biology Technology:
(Date:11/29/2016)... Nov. 29, 2016 BioDirection, a privately held ... for the objective detection of concussion and other traumatic ... successfully completed a meeting with the U.S. Food and ... test Pre-Submission Package. During the meeting company representatives reviewed ... a precursor to commencement of a planned pilot trial. ...
(Date:11/28/2016)... 28, 2016 "The biometric ... 16.79%" The biometric system market is in the ... the near future. The biometric system market is expected ... at a CAGR of 16.79% between 2016 and 2022. ... biometric technology in smartphones, rising use of biometric technology ...
(Date:11/22/2016)... 22, 2016   MedNet Solutions , an innovative ... of clinical research, is pleased to announce that the ... and Life Sciences Awards as "Most Outstanding in ... unprecedented year of recognition and growth for MedNet, which ... years. iMedNet ™ , MedNet,s ...
Breaking Biology News(10 mins):